Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price lowered by Oppenheimer from $53.00 to $52.00 in a research report released on Friday, Benzinga reports. The firm currently has an outperform rating on the stock. Several other equities research analysts have also weighed in on the stock. JPMorgan Chase & Co. increased their price […]
Blueprint Medicines (NASDAQ:BPMC) PT Raised to $125 00 at JMP Securities themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective increased by investment analysts at HC Wainwright from $125.00 to $135.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential […]
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective increased by JMP Securities from $114.00 to $125.00 in a report issued on Friday morning, Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock. BPMC has been the subject of a number of other research reports. Barclays lifted their target […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target boosted by equities research analysts at Barclays from $70.00 to $75.00 in a report released on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would suggest a potential downside of 30.23% from the […]